Title
The beneficial effects of the herbal medicine Di-huang-yin-zi (DHYZ) on patients with ischemic stroke: A Randomized, Placebo controlled clinical study

Permalink
https://escholarship.org/uc/item/36k913vm

Journal
Complementary Therapies in Medicine, 23(4)

ISSN
0965-2299

Authors
Yu, M
Sun, ZJ
Li, LT
et al.

Publication Date
2015

DOI
10.1016/j.ctim.2015.06.003

Peer reviewed
The beneficial effects of the herbal medicine Di-huang-yin-zi (DHYZ) on patients with ischemic stroke: A Randomized, Placebo controlled clinical study

Mei Yu, Zhi-Jun Sun, Lian-Tao Li, Hong-You Ge, Chang-Qin Song, Ai-Jun Wang

Shan Dong Medical College, Jinan, China
Laboratory for Experimental Pain Research, Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
Department of Surgery, University of California, Davis, Sacramento, CA 95817, USA

A R T I C L E  I N F O

Article history:
Received 18 February 2014
Received in revised form 20 May 2015
Accepted 2 June 2015
Available online 19 June 2015

Keywords:
Chinese medicine
DHYZ
Ischemic stroke
Complementary and alternative medicine

A B S T R A C T

Objectives: This study aimed to investigate the safety and therapeutic efficacy of herbal drug, Di Huang Yin Zi (DHYZ), in patients affected by ischemic stroke.

Methods: In this double blind, placebo-controlled study, a total of 100 patients with recent (less than 30 days) ischemic stroke were randomized to receive DHYZ or placebo for 12 weeks. Both groups also received rehabilitation therapy during the study period. As there were 13 dropouts, a total of 45 patients on DHYZ and 42 on placebo were available for analysis. The Fugl-Meyer Assessment (FMA) and Barthel index (BI) were assessed before treatment and at 4-week intervals.

Results: We observed that the FMA score and BI were increased, in both groups at week 4, 8 and 12 compared with the baseline. Furthermore, significantly better FMA score was observed in patients treated with DHYZ at week 8 and 12 (both \( P < 0.05 \)). BI was significantly higher in DHYZ group than in placebo group at weeks 12 (\( P < 0.05 \)). At week 12, the 95% Confidence Intervals (CI) of mean difference of FMA and BI also indicated that the differences between two groups were statistically significant. Compared to placebo, DHYZ produced significantly greater improvement in FMA grade at week 12 (44.4% versus 23.8%, \( \chi^2 = 4.09, P < 0.05 \)).

Conclusions: DHYZ showed good efficacy, safety and tolerability in patients affected by ischemic stroke. We conclude that DHYZ may be a useful therapeutic option in patients with ischemic stroke.

© 2015 Elsevier Ltd. All rights reserved.
1. Introduction

Stroke is the major cause of disability worldwide, and the high incidence of post-stroke disability brings a heavy burden to patients and their caregivers. This problem might be aggravated greatly in the next two decades due to the aging of population, especially in the developing countries.

Rehabilitation therapy may prevent sequelae or improve functional status after stroke, so patients with stroke are often transferred for rehabilitation when clinically stable. But still approximately 50% of the stroke patients need long-term care even they receive regular rehabilitation therapy. Many patients are dissatisfied with the poor recovery and seek for alternative therapy to improve the physical functions in recent years.

Alternative therapies, including herbal medicine, acupuncture/acupressure, and moxibustion are used by 42–80% of stroke patients in China. The chronic symptoms following a stroke such as spasticity, changed muscle tone, motor neuron excitability, and ankle plantar flexor spasticity can be alleviated after acupuncture treatment. In Japan, herbal remedies have also been used for neurological disorders since Song Dynasty (approximately 900 years ago). Previous clinical experiment has shown that DHYZ significantly improve neurological function in post-stroke patients.

2. Patients and methods

2.1. Study setting

This double-blind, placebo-controlled clinical trial was conducted at the Chang-Guo Hospital of Shandong province, China, between September 2010 and August 2013. The study protocol was approved by the Medical Ethical Committee of Chang-Guo Hospital in conformity with the Declaration of Helsinki and its subsequent amendment. A total of 100 patients with a recent ischemic stroke were recruited to the study (Fig. 1), and the treatment period lasted 12 weeks. All participants signed an informed consent document before entering the study. Each patient was evaluated by a neurologist specialized in clinical and rehabilitation assessment.

Inclusion criteria for this study were: age between 40 and 72 years, a recent (<30 days) ischemic stroke in anterior cerebral circulation. In addition, CT scan or MRI was applied to confirm diagnosis of ischemic stroke and exclude hemorrhagic stroke.

Exclusion criteria: infarction of the basilar artery system, treatment with thrombolytic, ischemic stroke combined with hemorrhage, a Mini-Mental State Examination score <23, seizure, history of previous stroke, severe aphasia, Severe dysphagia, pneumonia, urinary tract infections, atrial fibrillation, deep vein thrombosis.

2.2. Preparation of DHYZ and placebo

DHYZ is a combination of 13 herbal drugs. The quality of the constituent herbs was in accordance with the standards set out in the Pharmacopoeia of the People’s Republic of China, 2000 edition.

The content of known chemical constituents in a tablet of DHYZ derived from 3 g crude herbal mixture was evaluated by high-performance liquid chromatography with electrochemical detection (Table 1). The shelf life of DHYZ is 1 year. The placebo and DHYZ were prepared by Jinan Pharmaceutical (Jinan, Shandong, China) as described by Zhang et al. The water extract of the crude herbal materials was processed as described in the Pharmacopoeia of the People’s Republic of China, 2000 edition.

The resulting powder was formed into tablets, each tablet containing 3 g of the crude herbal mixture. The main ingredients of placebo are medical starch, edible caramel pigment (correcting color agent), bitter agent (the flavoring agent), both the placebo and herbal tablets were identical in shape, size, color and taste. Furthermore, to minimize the effect of the distinctive smell of herbal preparations on double blinding, the herbal tablets and placebo were all contained in blister packs made from plastic film and aluminium foil, with six tablets in each blister pack. The packs were distributed to the patients by a physician who was not involved in the study. The study investigators and patients were not aware of the identity of the administered medications.

2.3. Study procedures

A physician who was not involved in patient evaluation performed a computer-generated randomization procedure by using SPSS 15.0 software. The participants, based on the severity of the disease, age, gender were randomly allocated to two different treating groups in a 1:1 ratio.

The DHYZ and placebo treatments were commenced when the patients were transferred to the ward of rehabilitation centre. All patients were treated with rehabilitation under the standard regimen as needed including antiplatelet, lipolowering, antihypertensive, and antidiabetic medications. On top of rehabilitation and standard treatment, patients involved in this study received either DHYZ (18 g, twice daily) or placebo (18 g, twice daily) for 12 weeks.

During the study period, patients also received inpatient rehabilitation therapy consisting of 2 h of individual physiotherapy and 2 h of occupational therapy on 6 days each week.

2.4. Patient evaluation

Patients were assessed at baseline and after 4, 8 and 12 weeks’ treatment with DHYZ or placebo. The motor function scores of patients were assessed by the Fugl–Meyer assessment (FMA) scale. The maximum score is 66 points for the upper extremity, 34 points for the lower extremity. Patients were categorized into 3 grades according to their baseline FMA score at initiation of this trial: severe (0–50), moderate (50–84), and mild (85–99).

Activities of daily living (ADL), which was scored by Barthel index (Range 0–100; the higher the score, the greater the independence in ADL), was also assessed. Besides the neurological examination, all patients underwent electrocardiogram, blood routine, urine routine, renal function test, liver function test, electrolytes, prothrombin time (PT), and partial thromboplastin time (PIT) at first and every 4 weeks.

Side effects and tolerability were assessed by recording adverse events at each visit. All adverse events – reported, elicited, or observed – were recorded on the case report form, including the
date and time of onset, duration, severity, relationship to study drug, and action taken.

2.5. Statistical analysis

Results of FMA and BI at each measured point were expressed as the mean ±SD and assessed by the t-test; furthermore, if the value zero is excluded from the 95% CI of mean difference (FMA and BI), the results also means that the differences between groups are statistically significant.

The difference in the percentage of patients showing an improved FMA grade was assessed by the X2-test. A P-value of <0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS® software version 15.0 (SPSS Inc., Chicago, IL, USA).

3. Results

As there were 13 dropouts (5 patients in DHYZ group and 8 in placebo group), a total of 45 patients on DHYZ and 42 on placebo were available for analysis (Fig. 1). General baseline characteristics of the patients who complete the trial are shown in Table 2.

No serious side effects were observed, although 6 patients in the DHYZ group complained of nausea for several days, but this side effect disappeared later, and 5 patients in the placebo group reported nausea. The drug-induced nausea was attenuated by massage, and no patient in both groups left the study owing to side effects of medication.

FMA scores at weeks 4, 8 and 12 were significantly higher than at week 0 in both groups (all P＜0.05). There were no significant differences in motor scores between the DHYZ and placebo groups at weeks 4; however, the scores at week 8 and 12 were significantly
The formulation of DHYZ.

<table>
<thead>
<tr>
<th>Full scientific name</th>
<th>Herbal materials</th>
<th>%</th>
<th>Chemical constituent</th>
<th>mg/tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radix Rehmanniae preparata</td>
<td>Dry root</td>
<td>17</td>
<td>Catalpol</td>
<td>6.2</td>
</tr>
<tr>
<td>Radix Aconiti Lateralis Preparata (Zhi-Fuzi)</td>
<td>Dry root</td>
<td>4.3</td>
<td>Aconitine</td>
<td>0.16</td>
</tr>
<tr>
<td>Cortex Cinnamomi</td>
<td>Dry bark</td>
<td>4.3</td>
<td>Cinnamic aldehyde</td>
<td>3.1</td>
</tr>
<tr>
<td>Radix Ginseng</td>
<td>Dry root</td>
<td>8.5</td>
<td>Ginsenoside</td>
<td>6.6</td>
</tr>
<tr>
<td>Fructus Corni</td>
<td>Dry sarcocarp</td>
<td>6.4</td>
<td>Ursolic acid</td>
<td>5.4</td>
</tr>
<tr>
<td>Ramulus Loranthi</td>
<td>Dry stem with leaf</td>
<td>8.5</td>
<td>Oleanolic acid</td>
<td>3.8</td>
</tr>
<tr>
<td>Poria cocos Wolf</td>
<td>Dry sclerotium</td>
<td>8.5</td>
<td>Pachyman</td>
<td>114.8</td>
</tr>
<tr>
<td>Rhizoma Alismatis</td>
<td>Dry root</td>
<td>6.4</td>
<td>Alismol</td>
<td>0.23</td>
</tr>
<tr>
<td>Cortex Eucomnaiae</td>
<td>Dry bark</td>
<td>6.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angelica Sinensis</td>
<td>Dry root</td>
<td>8.5</td>
<td>Ferulic acid</td>
<td>13.8</td>
</tr>
<tr>
<td>Radix Ophiopogonis</td>
<td>Dry root</td>
<td>8.5</td>
<td>Ophiopogonin</td>
<td>18.4</td>
</tr>
<tr>
<td>Fructus Schisandrae Chinensis</td>
<td>Dry fruit</td>
<td>10.6</td>
<td>Schizandrin B</td>
<td>1.1</td>
</tr>
<tr>
<td>Glycyrrhiza uralensis Fisch</td>
<td>Dry root</td>
<td>2.1</td>
<td>Glycyrrhizic acid</td>
<td>0.53</td>
</tr>
</tbody>
</table>

Baseline characteristics of patients with ischemic stroke treated with DHYZ or placebo.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>DHYZ (n=45)</th>
<th>Placebo (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>60.7±12.2</td>
<td>58.1±10.7</td>
</tr>
<tr>
<td>M/F</td>
<td>30/15</td>
<td>28/14</td>
</tr>
<tr>
<td>Stroke onset to randomization, days</td>
<td>14.9±5.7</td>
<td>16.8±7.2</td>
</tr>
<tr>
<td>Stroke onset to first dose, days</td>
<td>15.9±7.7</td>
<td>17.8±7.2</td>
</tr>
</tbody>
</table>

**Previous history of cerebrovascular event**

| TIA | 3 (6.67%) | 2 (4.76%) |
| Ischemic stroke | 5 (11.11%) | 4 (9.52%) |

**Medical history of:**

| Hypertension | 36 (80%) | 32 (76.19%) |
| Diabetes | 15 (33.33%) | 13 (30.95%) |
| Hyperlipidemia | 24 (53.33%) | 20 (47.61%) |
| Myocardial infarction | 1 (2.22%) | 1 (2.38%) |
| Angina cordis | 1 (2.22%) | 2 (4.76%) |

**FMA grade**

| Severe (0–50) | 18 (40%) | 13 (30.95%) |
| Moderate (50–84) | 27 (60%) | 29 (60.05%) |
| Baseline FMA score | 48.0±12.4 | 51.0±13.8 |
| Baseline BI | 44.1±11.9 | 46.2±11.4 |

Data presented as mean ± SD or n of patients. DHYZ – Di Huang Yi Zi; BI – Barthel Index; FMA – Fugl-Meyer assessment.

higher (both \( P < 0.05 \)) in the DHYZ group than in the placebo group; and the 95% CI of FMA mean difference also indicated that the differences between two groups were statistically significant (Table 3). BI score increased significantly from baseline values during the treatment period (all \( P < 0.05 \)). In addition, at weeks 12 the scores were significantly higher (\( P < 0.05 \)) in the DHYZ group than in the placebo group; and the 95% CI of BI mean difference between two groups was also statistically significant (Table 4). At week 12, 20 patients (44.4%) in DHYZ group showed improved FMA grade (12 from grade severe to moderate, and 8 from grade moderate to mild) and 10 patients (23.8%) in the placebo group had improved FMA grades (6 from grade severe to moderate, and 4 from grade moderate to mild); the difference between two groups
Table 3
FMA score of patients with ischemic stroke treated with DHYZ or placebo (mean, the 95% CI of mean and mean difference).

<table>
<thead>
<tr>
<th>Weeks of treatment</th>
<th>DHYZ (n=45)</th>
<th>Placebo (n=42)</th>
<th>mean difference and 95% CI of mean difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>48.0(44.3, 51.7)</td>
<td>51.0(46.7, 55.3)</td>
<td>3.0 (−1.5, 8.5)</td>
</tr>
<tr>
<td>4</td>
<td>56.4(52.7, 60.1)</td>
<td>57.6(53.7, 61.5)</td>
<td>1.2 (−4.0, 6.4)</td>
</tr>
<tr>
<td>8</td>
<td>67.0(63.0, 71.0)</td>
<td>60.0(56.0, 64.0)</td>
<td>7.0 (1.6, 12.4)</td>
</tr>
<tr>
<td>12</td>
<td>71.8(67.6, 75.0)</td>
<td>65.3(61.1, 69.5)</td>
<td>6.5 (0.7, 12.3)</td>
</tr>
</tbody>
</table>

Table 4
BI score of patients with ischemic stroke treated with DHYZ or placebo (mean, the 95% CI of mean and mean difference).

<table>
<thead>
<tr>
<th>Weeks of treatment</th>
<th>DHYZ (n=45)</th>
<th>Placebo (n=42)</th>
<th>mean difference and 95% CI of mean difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>44.1(40.5, 47.7)</td>
<td>46.2(42.6, 49.8)</td>
<td>2.1 (−2.8, 7.0)</td>
</tr>
<tr>
<td>4</td>
<td>52.0(48.4, 55.6)</td>
<td>55.7(52.5, 58.9)</td>
<td>3.7 (−1.0, 8.4)</td>
</tr>
<tr>
<td>8</td>
<td>64.2(60.9, 67.5)</td>
<td>61.9(59.1, 64.7)</td>
<td>2.3 (−1.9, 6.5)</td>
</tr>
<tr>
<td>12</td>
<td>74.6(71.6, 77.6)</td>
<td>70.1(66.9, 73.3)</td>
<td>4.5 (0.3, 8.7)</td>
</tr>
</tbody>
</table>

4. Discussion

4.1. DHYZ may facilitate angiogenesis and increase blood flow in the ischemia region

Angiogenesis is a process wherein new blood vessels are formed, and some insults such as ischemia can induce angiogenesis and vascular remodeling. Through immunohistological analysis and mRNA studies, it was confirmed that angiogenesis was initiated within 48 h after ischemia occurred and last for up to a few weeks in rodent animal model.25–28

Radix Ginseng29 and Angelica Sinensis30 could facilitate the process of angiogenesis and induce neurogenesis. Radix Ginseng was also observed to suppress the formation of thrombin in blood coagulation.31 Radix Angelica Sinensis significantly improved cognitive function which was impaired by repetitive cerebral ischemia–reperfusion.32 Radix Aconiti Lateralis Preparata was reported to have vasodilatory and diuretic effects in patients with left ventricular failure.33 Cinnamaldehyde, one of the major ingredient in Cortex Cinnamomi, was shown to have the vasorelaxant effects.34 Radix Rehmanniae Preparata has been reported to improve peripheral microcirculation in various chronic diseases by facilitating blood flowing.35 Furthermore, its neuroprotective effects against neuronal and cognitive impairments induced by cerebral ischemia were also been confirmed.36

Poria cocos was proved to have protective effect against brain ischaemia–reperfusion injury.37

On the whole, some ingredients of DHYZ may have enhanced angiogenesis, and new blood vessels increased the blood flow in the affected region,38 thus further improving the exchange of oxygen and stimulated the neurogenesis.

4.2. The inhibitory effects of DHYZ against free radical in the ischemia region

There is strong evidence for the early occurrence of oxygen free radical formation and cell membrane lipid peroxidation in central nervous system injury.40 Free radicals are regarded to play a role in mediating ischemic neuronal damage, and in particular, reperfusion injury.41 A somewhat novel therapy to ischemic stroke is the use of free radical quenching agents.42

Several herbs in DHYZ have been reported to have inhibitory effects on the generation of oxygen free radicals, including Radix Ginseng,41 Radix Aconiti Lateralis Preparata,41 Cortex Cinnamomi,42–44 Radix Rehmanniae Preparata,45 Fructus Corni,46 Poria cocos,47 Radix Angelica Sinensis48 and Radix Glycyrrhiza.49 Furthermore, Fructus Corni has also been found to protect vascular endothelial cells from oxidant injury,40 while Glycyrrhiza uralensis Fisch has a promising role in the amelioration of ischaemia–reperfusion injury by acting as an antioxidant and oxygen–radical-scavenging agent.50

These studies show that some ingredients of DHYZ may be useful for the removal of pathologically produced free radicals associated to the ischemic damage.

4.3. The anti-apoptotic effect of DHYZ in the ischemia region

Apoptosis occurs in days after the stroke and a larger number of apoptotic cells could be identified in the ischemic penumbra.51 In
the rat model, electro-acupuncture demonstrated to have exerted anti-apoptotic effect on cerebral ischemia–reperfusion injury. Prioritization of DHYZ in visceral ischemia–reperfusion injury is essential. Radix Ginseng may exert a protective effect against apoptosis in PC12 neuronal cells. 

Porcine cecum may protect nerve cells by suppressing apoptosis induced by amyloid β. Prioritization of Radix Angelica Sinesis has a protective effect against cytotoxicity induced by hydrogen peroxide since it improves cellular antioxidant defence and inhibits the mitochondrial apoptotic pathway. Prioritization of Radix Glycyrrhiza has been shown to cause a cytoprotective effect against arsenite-induced cell death by the inhibition of caspase-3. Thus, the therapeutic effect of DHYZ might be associated with an anti-apoptotic mechanism in the ischemic area.

Other ingredients of DHYZ may also be beneficial to patients with ischemic stroke. For example, Ramulus Loranthi was proved to promote the activation of macrophages, suggesting that it may possess the potential to regulate immune responses. Cortex Eucommiae may increase central nervous system excitability in mice. We can infer that DHYZ have protective effect on brain-ischemia-induced damages through the actions of multiple components toward multiple targets.

The major strength of our study is that it is a well-designed study, conducted in a blinded, placebo-controlled manner. Nevertheless, compared to another trial of MLC601, which involved 1100 patients with ischemic stroke and statistically showed that MLC601 was no better than placebo, there are some limitations in this study: (1) it is only a first trial with a relatively low number of subjects; (2) it is not a multicenter study. The different components and mechanisms of action of DHYZ may account for the difference in the curative efficacy between DHYZ and MLC601; but, further confirmation of this study in larger studies is still required.

Furthermore, many questions remained to be answered, for instance, what the interactions of DHYZ with other drugs are, how long the duration of treatment should be, and whether it can be used for the patients with hemorrhagic stroke, etc. More clinical trials are needed to be performed to evaluate the safety and efficacy of DHYZ on stroke.

5. Conclusion

Traditional Chinese medicine is widely used in China and other Asian countries; but even in China, many rehabilitation physicians have strong reservations about its benefits and it is not a necessary part of standard rehabilitation. This trial provides evidence that the potential mechanism DHYZ involved with blood flow increase, anti-apoptotic and anti-free radical in the ischemia region. This study will provide useful information that DHYZ may be an effective adjuvant therapy for patients with ischemic stroke.

Acknowledgments

This study (8173152) was supported by the Natural Science Foundation of People’s Republic of China. None of the authors or the departments involved in this study has financial ties with the companies producing the medications used in this study. The authors thank Shu-hua Wang, MD, for the randomization and coding of DHYZ and placebo. We also thank physician Xin-li Ding, MD, and nurses Cai-Xia Liu, BS, and Lin Liu, BS, who were responsible for dispatching the medicines and recording the times and doses of taking medicine each day in this study.

References